Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
8.58
+0.02 (0.23%)
At close: Sep 3, 2025, 4:00 PM
8.56
-0.02 (-0.23%)
After-hours: Sep 3, 2025, 4:41 PM EDT
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Y-mAbs Therapeutics stock have a consensus rating of "Buy" and an average price target of $13.91, which forecasts a 62.12% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $23.
Price Target: $13.91 (+62.12%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 | 2 |
Buy | 4 | 4 | 4 | 4 | 4 | 3 |
Hold | 1 | 1 | 1 | 1 | 1 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 11 | 11 | 11 | 11 | 11 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $11 → $8.6 | Strong Buy → Hold | Downgrades | $11 → $8.6 | +0.23% | Aug 6, 2025 |
Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $26 → $8.6 | Strong Buy → Hold | Downgrades | $26 → $8.6 | +0.23% | Aug 6, 2025 |
Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 5, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $20 → $15 | Buy | Maintains | $20 → $15 | +74.83% | May 29, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +28.21% | May 19, 2025 |
Financial Forecast
Revenue This Year
84.47M
from 87.69M
Decreased by -3.67%
Revenue Next Year
96.27M
from 84.47M
Increased by 13.97%
EPS This Year
-0.84
from -0.67
EPS Next Year
-0.95
from -0.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 91.0M | 136.3M | |||
Avg | 84.5M | 96.3M | |||
Low | 77.7M | 84.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 3.8% | 61.3% | |||
Avg | -3.7% | 14.0% | |||
Low | -11.4% | -0.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.43 | -0.83 | |||
Avg | -0.84 | -0.95 | |||
Low | -1.14 | -1.15 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | |||
Avg | - | - | |||
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.